Frequently asked questions

Estimates vary by survey and definition. The National Comorbidity Survey Replication (NCS-R) reported a 12-month prevalence of about 19 percent for any anxiety disorder among U.S. adults using a structured diagnostic interview, with fieldwork conducted in 2001 to 2003. More recent national surveys, including NSDUH, NHIS, and BRFSS, use shorter symptom screeners and produce different anchors. No current ongoing U.S. survey replicates the full NCS-R diagnostic instrument. See the U.S. Anxiety Access Report in full.

Major guidelines (APA, NICE, VA/DoD) treat cognitive behavioral therapy and SSRIs as first-line for most adult anxiety disorders, with SNRIs as a closely related first-line pharmacotherapy option. Treatment selection considers severity, prior response, side-effect tolerance, comorbidity, and patient preference. See what meta-analyses say about CBT for anxiety and the SSRI/SNRI evidence.

Meaningful symptom change typically emerges between four and twelve weeks of consistent dosing. Anxiety can transiently worsen during the first one to two weeks, a pattern clinicians often anticipate in advance. Full response, where it occurs, may take eight to twelve weeks. Read on first-line pharmacotherapy for anxiety.

In September 2020, the FDA updated the boxed warning across the benzodiazepine class to describe risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions. The earlier class warning on combined opioid use remains in place. The 2020 update also instructs clinicians to assess patient risk before prescribing and to taper rather than stop abruptly. See the benzodiazepine evidence summary.

Systematic reviews report assessment, medication management, and several psychotherapy outcomes comparable to in-person care, with consistently high patient satisfaction. Telepsychiatry has limits for presentations that require physical examination, supervised medication administration, or acute in-person safety assessment. State licensure rules and the federal Ryan Haight Act shape what can be prescribed remotely. Read on telepsychiatry outcomes for anxiety.

See the state directory for links to your state mental health authority, NAMI affiliate, and FindTreatment.gov. The 988 Suicide and Crisis Lifeline operates nationwide via call, text, or chat.

No. AnxietyResearch.org is an editorial research publication. Articles summarize the published evidence and do not establish a clinician-patient relationship or substitute for individualized clinical evaluation. See the medical disclaimer.

Articles are reviewed by Shariq Refai, MD, MBA, a board-certified psychiatrist and the medical editor. Editorial review verifies factual claims against the cited sources and does not constitute the practice of medicine. See the author page and editorial policy.

AnxietyResearch.org is published by shrinkMD Publishing, LLC. The medical editor, Shariq Refai, MD, MBA, is also the founder of shrinkMD, an independent multistate telepsychiatry practice. The site is editorially independent of shrinkMD's clinical operations. This is disclosed sitewide. See disclosures.

Articles carry a Last reviewed date. Reviews recur on a quarterly cadence, with priority refresh when an authoritative new source (FDA action, major guideline update, large national survey release) materially changes a claim. See methods and corrections.

Anxiety is a normal emotion. Everyone feels it before a test, a hard conversation, or a real threat. An anxiety disorder is different. It's anxiety that's frequent, out of proportion to the situation, hard to control, and disruptive enough to interfere with daily life, and it usually lasts for months. The line between the two is about intensity, duration, and impairment, and it's a clinical judgment rather than a self-test. See the glossary entries on generalized anxiety disorder and panic disorder.

It depends on the survey, and the difference matters. A diagnostic survey, such as the National Comorbidity Survey Replication, uses a structured interview to decide whether a person meets the full criteria for a disorder. A symptom survey, such as the CDC Household Pulse Survey, uses a short screener to measure recent symptoms. Symptom surveys report higher numbers because symptoms are more common than full disorders. Neither is wrong. They answer different questions. See methods.

SSRIs and SNRIs, the first-line medications for most anxiety disorders, usually take four to six weeks to show a clear effect, and sometimes eight to twelve weeks for a full response. This slow onset is one reason people stop too early. Benzodiazepines act much faster, within about an hour, but are generally limited to short-term use. See the SSRIs and SNRIs evidence summary.

For most adult anxiety disorders, both CBT and first-line medication are reasonable first choices, and major guidelines list them side by side. Research hasn't shown one to be clearly better for everyone. The choice usually depends on preference, severity, access, prior response, and side-effect tolerance. For moderate to severe anxiety, combining the two can help. See what the evidence says about anxiety treatment.

Benzodiazepines reduce acute anxiety quickly and have a real role for short-term or occasional use. The concern is long-term use, which carries risks of tolerance, dependence, and withdrawal. The FDA updated benzodiazepine labeling in 2020 to strengthen these warnings, and there's a boxed warning against combining them with opioids. They're also flagged as potentially inappropriate for older adults. See the benzodiazepines evidence summary.

First-line treatments produce meaningful improvement for many people, but relapse is common, especially after treatment stops. Some evidence suggests CBT may protect against relapse better than medication alone, possibly because the skills remain available to the patient. Long-term follow-up beyond one to two years is limited in the research. See why a single study shouldn't change treatment.

Usually because they studied different things. Two studies of the same treatment can differ in who they enrolled, how they measured the outcome, how long they followed people, and what they compared the treatment against. Those differences, not error, explain most apparent contradictions. This is also why a systematic review of many studies is more reliable than any single one. See why mental health studies disagree.

Most don't, in any given year. Analysis of the National Comorbidity Survey Replication found that about 37 percent of U.S. adults with any anxiety disorder received any treatment in a year, and only about a third of those treated received care that met the survey's definition of minimally adequate. See the U.S. Anxiety Access Report.

For assessment, medication management, and several talk therapies, research finds telepsychiatry produces outcomes broadly comparable to in-person care, with high patient satisfaction. Its clearest benefit is access in areas short of clinicians. It isn't suited to psychiatric emergencies, and it operates within state licensure rules and controlled-substance prescribing rules. See the telepsychiatry evidence summary.

No. The site is an educational research publication. It summarizes studies, data, and clinical guidelines. It doesn't diagnose, treat, prescribe, or give advice for any individual, and reading it doesn't create a clinician-patient relationship. For a personal medical question, see a licensed clinician. In a crisis, call or text 988. See the medical disclaimer.

The site prefers the strongest synthesized evidence available. Systematic reviews and meta-analyses come first, then clinical practice guidelines, then government public-health data and large epidemiologic studies, and then individual peer-reviewed studies clearly labeled as such. Every statistic names its source and the date it was accessed. See methods.

Both have evidence for a modest benefit, especially for milder symptoms, and both carry broader health value. Neither has been shown to replace first-line treatments such as CBT or medication for a diagnosed anxiety disorder. They're better understood as helpful parts of a plan than as stand-alone treatments. See the evidence summaries on exercise and anxiety symptoms and on mindfulness-based interventions.